Vaccines to Prevent Meningitis: Historical Perspectives and Future Directions

Area of Science:

• * Infectious Diseases
• * Immunology
• * Public Health

Background:

• * Meningitis remains a global health concern despite vaccine advancements.
• * The Global Roadmap to Defeat Meningitis by 2030 prioritizes vaccination strategies.
• * Current vaccines have varying degrees of success and accessibility.

Purpose of the Study:

• * To examine current vaccination efforts against major bacterial meningitis causes.
• * To review future strategies for meningitis prevention through vaccination.
• * To highlight progress and challenges in global meningitis vaccine deployment.

Main Methods:

• * Review of global vaccination programs and vaccine development pipelines.
• * Analysis of vaccine accessibility, cost-effectiveness, and serotype coverage.
• * Examination of progress in specific meningitis types like Hib, pneumococcal, meningococcal, and GBS.

Main Results:

• * Haemophilus influenzae type B (Hib) vaccination is globally advanced and widely available.
• * Pneumococcal conjugate vaccines are more accessible but face access challenges and incomplete serotype coverage.
• * Meningococcal serogroup A vaccine deployment in Africa is successful, yet other serogroups persist.
• * Neonatal meningitis prevention lags, with no Group B Streptococcus (GBS) vaccine in Phase 3.

Conclusions:

• * Global meningitis control relies heavily on vaccination, with notable successes but persistent gaps.
• * Challenges include vaccine affordability, access for low-income countries, and comprehensive serotype coverage.
• * Future efforts must address neonatal meningitis and expand protection against all major serogroups.